Bank of Montreal Can Purchases 18,532 Shares of Hologic, Inc. (NASDAQ:HOLX)

Bank of Montreal Can raised its position in Hologic, Inc. (NASDAQ:HOLX) by 3.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 492,210 shares of the medical equipment provider’s stock after acquiring an additional 18,532 shares during the quarter. Bank of Montreal Can owned approximately 0.21% of Hologic worth $39,780,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Cetera Investment Advisers lifted its holdings in Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after acquiring an additional 13,380 shares during the period. Andra AP fonden lifted its holdings in Hologic by 224.5% in the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock valued at $7,083,000 after acquiring an additional 66,000 shares during the period. Swedbank AB raised its stake in shares of Hologic by 5.2% in the second quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock worth $121,060,000 after buying an additional 80,575 shares during the period. GAMMA Investing LLC lifted its position in shares of Hologic by 17.9% during the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 582 shares in the last quarter. Finally, Comerica Bank lifted its position in shares of Hologic by 40.9% during the 1st quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock valued at $8,580,000 after buying an additional 31,967 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on HOLX shares. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. lifted their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Leerink Partners lowered their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Evercore ISI lifted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Performance

NASDAQ:HOLX opened at $79.44 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The stock’s 50 day simple moving average is $80.28 and its two-hundred day simple moving average is $78.42. The company has a market cap of $18.45 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 2.51 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the company posted $0.89 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.